Evotec strengthens its French connection, pledging to drop $120M into Toulouse plant for Covid-19 antibodies
Much of the recent focus on manufacturing capacity for Covid-19 has been on vaccines, and for good reason, too. But countries are also hoping to build a big enough footprint to produce pandemic-level monoclonal antibodies, and now France is working with Germany’s Evotec to stay prepared.
Evotec will lay out $120 million with a $60 million boost from multiple French governments and investors to build a new biologics facility in Toulouse that will expand its capacity to produce therapeutic antibodies for Covid-19, the German CDMO and biotech said this week.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 104,600+ biopharma pros reading Endpoints daily — and it's free.